OUR MISSION
Deliver quality recombinant proteins and GMP enzymes with a commitment to reliability, speed, and innovation.
Expertly Designing & Manufacturing Recombinant Proteins & Enzymes
3000+ Catalog & Custom Production
MHC Monomers & Tetramers
Antibody Target Proteins
Gene Editing Reagents
RNA Synthesis Enzymes
Cell Therapy Proteins
Curated protein catalog driven by:
INNOVATION
Our catalog is carefully curated to align with emerging trends in drug development, adding proteins that are relevant to current research demands
QUALITY
Each product undergoes stringent quality verification before approval into the catalog
RELIABILITY
We ensure a consistent and reliable supply of each product by validating our production capabilities for long-term availability
Why researchers choose KACTUS
for protein and enzyme solutions
Consistent bioactivity & stability
Verified product quality via activity assays such as SPR, ELISA, and BLI and analytical techniques to ensure purity and size
Catalog & custom solutions
Readily available off-the-shelf products, as well as custom protein production services
Tackling difficult proteins
History of delivering solutions for challenging protein expression, including transmembrane proteins and MHC complexes
Leading with responsibility
Our commitment to sustainability
Our commitment to sustainability
Recyclable packaging designed to minimize waste while maintaining product integrity
Our journey from
inception to innovation
MARCH 2018
KACTUS is Founded
KACTUS embarked on its journey to deliver innovative recombinant proteins solutions, addressing the unmet demands of researchers and the challenges posed by complex protein expression.
JULY 2018
First to express Claudin 18.2
We became the first company to successfully express full-length multi-transmembrane protein Claudin 18.2. This showcased the robustness of our protein engineering capabilities.
2019
SAMS™ Technology Platform
After successfully expressing complex proteins including MHCs and transmembrane proteins, we conceptualized our structure-based protein expression platform, Structure-Aided Multiplex Screening (SAMS™).
2020
Established GMP Enzyme Enterprise
We established our cGMP-compliant enzyme manufacturing facility in 2021, underscoring our commitment to commercialization solutions. This facility provide a range of GMP-Grade mRNA and gene editing enzymes.
2021
GMP Auditing & DMF Submissions
We passed onsite audits for our GMP-compliant facilities by gene editing and mRNA vaccine clients. In alignment with our commitment to regulatory adherence, we filed Drug Master Files (DMF) for our key GMP enzyme products.
FEBRUARY 2022
Making Products Accessible
Our global operational footprint was expanded to include additional warehouse sites, international distributors, ready-to-ship products, and fast shipping speeds. Quality customer service is at the forefront of our logistics operations.
DECEMBER 2022
GMP Enzyme in Clinical Trial
Our GMP-Grade CRISPR Cas9 Enzyme was approved for use in Reforgene Medicine's clinical trial to treat beta-thalassemia, standing as a testament to the credibility of our GMP production facilities and regulatory support.
NOVEMBER 2023
First Commercial Base Editor
KACTUS proudly announced the global release of AccuBase®, the first commercially-available base editor, revolutionizing precision gene editing with unparalleled accuracy and efficiency.
JULY 2024
Expanding Membrane Proteins
We expanded our transmembrane protein display platforms to include nanodiscs, allowing our customers to better overcome membrane protein display challenges.
TODAY
Fueled by Purpose
Today, our solutions have expanded to 3000+ recombinant proteins, 25+ GMP enzymes, and custom protein expression. We continue to launch new products and services that focus on current challenges in R&D and commercialization.
Empowering your research with expert protein and enzyme solutions
Empowering your research with expert protein and enzyme solutions
Elevating protein science with advanced expression
SAMS™ Technology Platform
Our products are developed using our proprietary engineering platform, SAMS™: Structure Aided Multiplex Screening. With this structure- and expression-based platform, we have produced difficult-to-express targets such as full-length CCR8 and Claudin 18.2.
Advantages of SAMS™
Design Expertise
Our expertise in structural biology, protein design, and enzymatic studies, along with our SAMS™ platform, will help you create a protein configuration that will be functional for your application while also optimizing purity & yield.
Tailored Expression Systems
After generating 3D models of your protein/enzyme, we test the configurations in various expression systems to optimize protein folding, maximize bioactivity, and enhance stability.
Quality Bulk Supply
We'll take your protein configuration from bench to large-scale production. Our quality control systems ensure batch-to-batch consistency and our facilities are prepared for consistent high-quantity production.
Our values
REPRODUCIBILITY
Consistent performance across product lots for reliable research outcomes
Responsiveness
Committed to rapid, responsive communication and fast shipping
Resolve
Welcoming challenges in protein expression with expertise in overcoming biotechnological barriers
Reasoning
Protein engineering grounded in rationale principles and structural biology for optimal functionality
Relevance
Evolving product lines to meet drug development demands, ensuring relevance and utility in current research
Responsibility
Embracing environmental responsibility with sustainable packaging solutions to minimize waste
Primary Keyword or Phrase
60 Hickory Drive
Waltham, MA 02451
United States
About KACTUS: Quality Recombinant Proteins and Enzymes